Clinical Trial Details

If you are a patient or a caregiver and would like to learn more our cancer clinical trials
call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials) or
email cancerclinicaltrials@bsd.uchicago.edu.

The primary hypothesis of this study is that outcomes for patients with biochemically
recurrent prostate cancer following radical prostatectomy will be improved by the addition
of enzalutamide for 6-months compared to standard-of-care salvage radiation therapy to allow
for further study in the definitive phase III setting. This study builds on the prior
success of high-dose bicalutamide (for 24 months) when combined with salvage external
radiation therapy (XRT), while using a newer more potent anti-androgen for a shorter
duration of time (6 months) in an effort to minimize adverse effects.